uniQure N.V.

Equities

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
5.07 ^USD	+0.20%		0.00%	-25.11%

May. 08	Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	MT
May. 07	UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2022

February 27, 2023 at 07:20 am EST

uniQure N.V. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 1.72 million. Revenue was USD 106.48 million compared to USD 524 million a year ago.

Net loss was USD 126.79 million compared to net income of USD 329.59 million a year ago. Basic loss per share from continuing operations was USD 2.71 compared to basic earnings per share from continuing operations of USD 7.17 a year ago. Diluted loss per share from continuing operations was USD 2.71 compared to diluted earnings per share from continuing operations of USD 7.04 a year ago.

Latest news about uniQure N.V.

Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating	May. 08	MT
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M	May. 07	MT
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	Apr. 12	CI
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating	Apr. 02	MT
UniQure N.V.(NasdaqGS:QURE) dropped from S&P Biotechnology Select Industry Index	Mar. 17	CI
Mizuho Securities Adjusts Price Target on uniQure to $7 From $10, Maintains Neutral Rating	Mar. 04	MT
Goldman Sachs Downgrades UniQure to Neutral From Buy, Cuts Price Target to $8 From $63	Feb. 29	MT
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
RBC Cuts Price Target on UniQure to $28 From $33, Keeps Outperform Rating, Speculative Risk Qualifier	Jan. 03	MT
Kempen Downgrades UniQure to Neutral From Buy, Cuts Price Target to $18 From $28	Dec. 22	MT
Transcript : UniQure N.V. - Special Call	Dec. 19
Mizuho Downgrades uniQure to Neutral From Buy, Cuts Price Target to $10 From $52	Dec. 19	MT
UniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease	Dec. 19	CI
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	Nov. 29	MT
UniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease	Nov. 29	CI
Worldwide Healthcare Trust net asset value slips in volatile markets	Nov. 23	AN
Goldman Sachs Increases Price Target on uniQure to $63 From $56, Maintains Buy Rating	Nov. 08	MT
RBC Cuts Price Target on uniQure to $33 From $37, Keeps Outperform, Speculative Risk	Nov. 08	MT
UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (QURE) UNIQURE Posts Q3 Revenue $1.4M	Nov. 07	MT
UniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy Annual Meeting	23-10-24	CI
UniQure N.V. Announces Chief Scientific Officer Changes	23-10-05	CI
UniQure to Cut 114 Jobs as Part of Restructuring Plan to Lower Expenses	23-10-05	MT
UniQure to lay off about 20% of workforce	23-10-05	RE

Chart uniQure N.V.

Duration

Period

More charts

Company Profile

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for uniQure N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.664 EUR

Average target price

18.07 EUR

Spread / Average Target

+287.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
UNIQURE N.V.	-25.11%	246M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.32%	22.28B
GENMAB A/S	-5.71%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs